Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients

Teta, Daniel; Lüscher, Brigitte Landtwing; Gonvers, Jean‐Jacques; Francioli, P.; Phan, Olivier; Burnier, Michel

doi:10.1093/ndt/gfh747

Cited by 49 publications

(41 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They were among the principal reasons for dose reduction or treatment discontinuation. [24][25][26] Diminishing hemoglobin levels, which could occur during treatment, might be maintained by increasing the erythropoietin dose. [24] The first published experience with pegylated interferon α-2a for the treatment of chronic HCV infection in hemodialysis patients was conducted on two patients with chronic hepatitis C and one with acute hepatitis C infection.…”

Section: Discussionmentioning

confidence: 99%

“…[24] The first published experience with pegylated interferon α-2a for the treatment of chronic HCV infection in hemodialysis patients was conducted on two patients with chronic hepatitis C and one with acute hepatitis C infection. [25] The dose of 180 μg pegylated interferon α-2a was set for the initiation of treatment. SVR was observed in both patients with chronic infection.…”

Section: Discussionmentioning

confidence: 99%

“…These results were comparable to the ones obtained in a few other studies involving hemodialysis patients with chronic HCV infection and treated with the same formulation of modified interferon α-2a. [22,25,26] During treatment, the patients had predictable and manageable decreases of hemoglobin level, neutrophil, and platelet count. Pegylated interferon α-2a was well tolerated, and laboratory abnormalities were moderate.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Treatment of Hepatitis C in Hemodialysis Patients with Pegylated Interferon α-2a as Monotherapy

et al. 2007

View full text Add to dashboard Cite

Background. The high prevalence of hepatitis C virus (HCV) infection in hemodialysis patients is of great concern because they have a higher rate of mortality than HCV-negative hemodialysis patients. The aim of the study was to evaluate the efficacy and safety of pegylated interferon α-2a monotherapy in hemodialysis patients with chronic HCV infection. Methods. Fourteen dialysis patients with chronic HCV infection were scheduled to receive 135 μg pegylated interferon α-2a subcutaneously, once a week, after dialysis session for a period of 48 weeks. Efficacy and safety were assessed by end of treatment viral response, sustained viral response, biochemical response, and adverse events. Serum HCV RNA levels were assessed using reverse transcriptase polymerase chain reaction (RT-PCR), while HCV genotype was analyzed by RT-PCR followed by hybridization of amplified products. Results. Of the 14 patients enrolled in the study, 9 completed treatment. Eight patients (57%) had undetectable levels of HCV RNA at the end of treatment, while one patient remained positive. Two (14.3%) patients were discontinued because of insufficient therapeutic response. Three patients (21.34%) did not finish treatment because serious adverse events occurred: one patient with bronchopneumonia and one with pericarditis were discontinued from treatment, while one patient died due to cerebral hemorrhage. Sustained viral response was present in 36% of the patients (5/8 patients) at the end of the follow up

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of Hepatitis C in Hemodialysis Patients with Pegylated Interferon α-2a as Monotherapy

et al. 2007

View full text Add to dashboard Cite

show abstract

“…15 PEG IFNs are an attractive option for the treatment of HCV-infected HD patients. [9][10][11][12][13] Although PEG IFN alpha-2b is mainly excreted by the kidneys, 14,22 PEG IFN alpha-2a, because of its pharmacokinetic properties and its prevalent hepatic excretion, could have a greater utilization rationale in patients with various degrees of kidney impairment or with endstage disease. 14 Pharmacokinetics studies have confi rmed the feasibility of PEG IFN alpha-2a therapy at full dosages in patients with creatinine clearance as low as 20 mL/ minute.…”

Section: Peg-ifn Alpha-2a Monotherapy In Hd Hepatitis C Patientsmentioning

confidence: 99%

“…[9][10][11][12][13] In particular, PEG-IFN alpha-2a, because of its hepatic clearance, is an attractive option for patients with ESRD undergoing HD. 14 The aim of this pilot study was to investigate the effi cacy, safety, and tolerability of PEG-IFN alpha-2a in 10 HD patients with chronic hepatitis C.…”

mentioning

confidence: 99%

Monotherapy with Pegylated Interferon Alpha‐2a in Hemodialyzed Patients with Chronic Hepatitis C

Zoppoli

Maio²,

Artioli

et al. 2008

Dialysis & Transplantation

View full text Add to dashboard Cite

BACKGROUND In our pilot study, we aimed to treat a group of HCV-infected HD patients with pegylated interferon (PEG-IFN) alpha-2a, a new and potentially efficacious therapeutic possibility. METHODS We treated 10 consecutively enrolled chronic hepatitis C hemodialysis (HD) patients (5 men, 5 women; ages 31-70 years; 7 with genotypes 1-4, 3 with genotypes 2-3) with PEG-IFN alpha-2a (135 μg/week) for 24 weeks (genotypes 2-3) or for 48 weeks (genotypes 1-4). Primary end points were sustained viral response (SVR) rate and safety and tolerability profiles. Secondary end points were rapid response (after 12 weeks of treatment), and response at the end of therapy. RESULTS Viral load reduction was observed in all the patients after 12 weeks of treatment. Seven were HCV-RNA negative and continued therapy. Five patients dropped out before the completion of therapy because of significant adverse events (pancytopenia, severe weight loss). PEG-IFN alpha-2a was reduced to 90 μg/week in 5 patients within the first 4 weeks of therapy. Overall, SVR was 20% at the end of follow-up. CONCLUSION PEG-IFN alpha-2a is efficacious in inducing a fast virological response (12 weeks of therapy) in 70% of HCV-infected HD patients and a considerable fall in liver cytolysis enzymes blood values. The use of granulocyte colony-stimulating factor for neutropenia, starting with lower initial doses of PEG-IFN alpha-2a (e.g., 90 μg/week) or in combination with ribavirin, after appropriate dose adjustment studies, should be evaluated in randomized prospective studies

show abstract

Management of HCV in Dialysis Patients

Fabrizi

Martin

2010

Clinical Dilemmas in Viral Liver Disease

View full text Add to dashboard Cite

Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients

Cited by 49 publications

References 6 publications

Treatment of Hepatitis C in Hemodialysis Patients with Pegylated Interferon α-2a as Monotherapy

Treatment of Hepatitis C in Hemodialysis Patients with Pegylated Interferon α-2a as Monotherapy

Monotherapy with Pegylated Interferon Alpha‐2a in Hemodialyzed Patients with Chronic Hepatitis C

Management of HCV in Dialysis Patients

Contact Info

Product

Resources

About